Veterinary Medicines

Rabisin suspension injectable

Authorised
  • Rabies virus, Inactivated
Download as PDF

Product identification

Medicine name:
Rabisin suspension injectable
Rabisin injektionssuspension
Active substance:
  • Rabies virus, Inactivated
Target species:
  • Sheep
  • Cattle
  • Horse
  • Cat
  • Dog
  • Mustelids
Route of administration:
  • Intramuscular use
  • Subcutaneous use

Product details

Active substance and strength:
  • Rabies virus, Inactivated
    1.00
    international unit(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Sheep
      • Meat and offal, milk
        0
        day
    • Cattle
      • Meat and offal, milk
        0
        day
    • Horse
      • Meat and offal, milk
        0
        day
  • Subcutaneous use
    • Sheep
      • Meat and offal, milk
        0
        day
    • Cattle
      • Meat and offal, milk
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AA02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Luxembourg
Available in:
  • Luxembourg
Package description:
  • Rabisin 10 Vials x 1ml Suspension for injection

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Boehringer Ingelheim Animal Health Belgium S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Animal Health France
Responsible authority:
  • Ministry Of Health And Social Security
Authorisation number:
  • V 344/86/12/0337
Date of authorisation status change:

Documents

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 15/03/2023
Download

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 15/03/2023
Download